Display options
Cite
Mohammadbeigi A, Moshiri E, Mohammadsalehi N, et al. Dyslipidemia Prevalence in Iranian Adult Men: The Impact of Population-Based Screening on the Detection of Undiagnosed Patients. World J Mens Health. 2015;33(3):167-73doi: 10.5534/wjmh.2015.33.3.167.
Mohammadbeigi, A., Moshiri, E., Mohammadsalehi, N., Ansari, H., & Ahmadi, A. (2015). Dyslipidemia Prevalence in Iranian Adult Men: The Impact of Population-Based Screening on the Detection of Undiagnosed Patients. The world journal of men's health, 33(3), 167-73. https://doi.org/10.5534/wjmh.2015.33.3.167
Mohammadbeigi, Abolfazl, et al. "Dyslipidemia Prevalence in Iranian Adult Men: The Impact of Population-Based Screening on the Detection of Undiagnosed Patients." The world journal of men's health vol. 33,3 (2015): 167-73. doi: https://doi.org/10.5534/wjmh.2015.33.3.167
Mohammadbeigi A, Moshiri E, Mohammadsalehi N, Ansari H, Ahmadi A. Dyslipidemia Prevalence in Iranian Adult Men: The Impact of Population-Based Screening on the Detection of Undiagnosed Patients. World J Mens Health. 2015 Dec;33(3):167-73. doi: 10.5534/wjmh.2015.33.3.167. Epub 2015 Dec 23. PMID: 26770936; PMCID: PMC4709432.
Copy Download .nbib Format: NLM
Share it on

World J Mens Health. 2015 Dec;33(3):167-73. doi: 10.5534/wjmh.2015.33.3.167. Epub 2015 Dec 23.

Dyslipidemia Prevalence in Iranian Adult Men: The Impact of Population-Based Screening on the Detection of Undiagnosed Patients.

The world journal of men's health

Abolfazl Mohammadbeigi, Esamil Moshiri, Narges Mohammadsalehi, Hossein Ansari, Ali Ahmadi

Affiliations

  1. Department of Epidemiology and Biostatistics, Health Policy and Promotion Research Center, Qom University of Medical Sciences, Qom, Iran.
  2. Department of Anesthesiology, Arak University of Medical Sciences, Arak, Iran.
  3. Health Policy and Promotion Research Center, Qom University of Medical Sciences, Qom, Iran.
  4. Health Promotion Research Center, Department of Epidemiology and Biostatistics, Zahedan University of Medical Sciences, Zahedan, Iran.
  5. Department of Epidemiology and Biostatistics, Shahrekord University of Medical Sciences, Shahrekord, Iran.

PMID: 26770936 PMCID: PMC4709432 DOI: 10.5534/wjmh.2015.33.3.167

Abstract

PURPOSE: Dyslipidemia has been established as one of the most important modifiable risk factors for cardiovascular disease. Due to the higher prevalence of dyslipidemia in males, this study aimed to estimate the prevalence of dyslipidemia in Iranian urban men.

MATERIALS AND METHODS: A screening program was conducted in 845 Iranian men 25 years of age and older in 2014. A health interview survey was conducted to evaluate the prevalence of self-reported dyslipidemia and to collect demographic data, as well as serum lipid profile screening by a reference laboratory. Lipoprotein levels was categorized based on the Adult Treatment Panel III criteria and the data were analyzed using the chi-square test and analysis of variance.

RESULTS: The overall prevalence of dyslipidemia was 51.8%, and the prevalence of various forms of dyslipidemia was as follows: hypercholesterolemia (≥240 mg/dL), 11.4%; hyper-low-density lipoprotein cholesterol (≥160 mg/dL), 9.6%; hypertriglyceridemia (≥200 mg/dL), 25%; and hypo-high-density lipoprotein (HDL) cholesterol (<40 mg/dL), 34.3%. With the exception of hypo-HDL, all forms of dyslipidemia were significantly less common in men over 65 years of age (p<0.05).

CONCLUSIONS: The prevalence of hypo-HDL and hypertriglyceridemia was higher than expected in Iranian adult men, with half of men 25 years of age and older affected by at least one form of dyslipidemia. A large gap in primary and secondary care was observed, because nearly 80% of patients with dyslipidemia were unaware of their status. Urgent preventive programs and lifestyle changes are necessary to reduce the prevalence of cardiovascular risk factors.

Keywords: Dyslipidemia; Hypercholesterolemia; Hypertriglyceridemia; Male; Metabolic diseases

References

  1. Chin J Physiol. 2002 Dec 31;45(4):187-97 - PubMed
  2. Endocrine. 2008 Aug-Dec;34(1-3):36-51 - PubMed
  3. J Clin Lipidol. 2014 Mar-Apr;8(2):206-16 - PubMed
  4. Circulation. 2002 Dec 17;106(25):3143-421 - PubMed
  5. Osong Public Health Res Perspect. 2014 Jun;5(3):169-75 - PubMed
  6. JAMA. 2003 Jan 1;289(1):76-9 - PubMed
  7. Pak J Pharm Sci. 2009 Jan;22(1):62-7 - PubMed
  8. J Clin Lipidol. 2010 Jan-Feb;4(1):53-8 - PubMed
  9. Diabetes Res Clin Pract. 2005 Jul;69(1):63-77 - PubMed
  10. Metab Syndr Relat Disord. 2008 Sep;6(3):187-95 - PubMed
  11. Iran Red Crescent Med J. 2013 May;15(5):363-70 - PubMed
  12. JAMA. 2001 May 16;285(19):2486-97 - PubMed
  13. Diabetes Metab J. 2012 Feb;36(1):43-55 - PubMed
  14. J Cardiovasc Dis Res. 2012 Jan;3(1):26-31 - PubMed
  15. J Family Med Prim Care. 2015 Jan-Mar;4(1):35-8 - PubMed
  16. Clin Ther. 2007 Apr;29(4):742-50 - PubMed
  17. Public Health. 2013 Jul;127(7):661-7 - PubMed
  18. J Res Health Sci. 2015 Winter;15(1):37-41 - PubMed
  19. Am Heart J. 2008 Jul;156(1):112-9 - PubMed
  20. J Assoc Physicians India. 2008 Feb;56:99-102 - PubMed
  21. Metabolism. 2007 Dec;56(12):1666-72 - PubMed
  22. J Epidemiol Glob Health. 2013 Sep;3(3):139-46 - PubMed

Publication Types